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ABSTRACT
To date, targeted therapy for pancreatic ductal adenocarcinoma (PDAC) remains 
largely unsuccessful in the clinic. Current genomics-based technologies are unable 
to reflect the quantitative, dynamic signaling changes in the tumor, and require 
larger tumor samples that are difficult to obtain in PDAC patients. Therefore, a 
highly sensitive functional tool that can reliably and comprehensively inform intra-
tumoral signaling events is direly needed to guide treatment decision. We tested 
the utility of a highly sensitive proteomics-based functional diagnostic platform, 
Collaborative Enzyme Enhanced Reactive-immunoassay (CEERTM), on fine-needle 
aspiration (FNA) samples obtained from 102 patients with radiographically-evident 
pancreatic tumors. Two FNA passes were collected from each patient, hybridized 
to customized chips coated with an array of capture antibodies, and detected using 
two enzyme-conjugated antibodies which emit quantifiable signals. We demonstrate 
that this technique is highly sensitive in detecting total and phosphorylated forms 
of multiple signaling molecules in FNA specimens, with reasonable correlation of 
marker intensities between two different FNA passes. Notably, signals of several 
markers were significantly higher in PDAC compared to non-cancerous samples. In 
PDAC samples, we found high total c-Met signal to be associated with poor survival, 
and confirmed this finding using an independent PDAC tissue microarray.
INTRODUCTION
To date, the prognosis for pancreatic ductal 
adenocarcinoma (PDAC) remains dismal. Complete 
surgical resection offers the only chance for cure, but is 
limited to a small fraction of patients who are diagnosed 
at early stage. Even then, most patients who undergo 
seemingly successful resection eventually succumb to 
disease relapse despite adjuvant treatment [1]. Underlying 
the aggressive nature of PDAC is a complex, deregulated 
signaling circuitry woven by several genetic alterations 
such as oncogenic mutations of KRas, overexpression 
of EGFR/HER family members, and loss of key tumor 
suppressors including p53, CDKN2A and SMAD4, 
which cooperatively enhance the survival of PDAC cells 
and resist the killing effect of therapies [2-5]. Although 
targeting these deregulated signaling events holds 
promise to improve the outcome of PDAC patients, 
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clinical success remains limited [6]. The advent of next 
generation sequencing technologies has helped realize 
the goal of “personalized oncology” by allowing patients 
to be allocated to clinical trials tailored towards genomic 
alterations found in their tumors [7]. These techniques, 
despite being promising, have met with their own set 
of challenges, which include low tumor cellularity 
that is typical of PDAC, tumor heterogeneity, clonal 
evolution, and importantly, frequent discordance between 
genotype and cancer phenotype [8]. On the other hand, 
a “functional” diagnostic based on proteomics may serve 
as a useful complementary tool by providing the most 
direct link to the phenotype of cancer cells [9]. As most 
targeted agents are signaling modulators, a proteomics-
based diagnostic that can inform the biological effect 
of targeted agents in real-time within the tumor will 
be extremely helpful in assessing treatment response, 
identifying potential resistance mechanisms and guiding 
further treatment decision, all of which are impossible 
using archived tumor samples. 
In this study, we report the use of a multiplex 
proteomic-based assay, Collaborative Enzyme Enhanced 
Reactive-immunoassay (CEERTM), that is clinically 
feasible, highly sensitive and specific. This platform 
was previously shown to be successful in detecting 
rare “HER2-activated” circulating tumor cells in 
HER2-negative metastatic breast cancer patients [10], 
indicating its high sensitivity and ability to provide 
potentially actionable information beyond the genomic 
and transcriptomic levels. We show that the CEER™ 
platform allows simultaneous detection of the abundance 
and activation status of multiple key signaling molecules 
(or “markers”) that are uniquely deregulated in PDAC 
but not in normal tissues obtained from fine-needle 
aspirations (FNA), indicating high specificity and 
sensitivity. Encouragingly, while correlating the intensity 
of each marker to prognosis we found high c-MET signal 
in FNA specimens to be associated with poor prognosis, 
which is consistent with published literature based on 
immunohistochemistry of resected specimens, indicating 
great potential of this platform in studies of advanced, 
inoperable PDAC tumors in the future. Finally, we 
identified markers with previously unreported prognostic 
significance that may unveil novel understanding to PDAC 
biology. 
RESULTS
Patient characteristics
Between year 2010-2012, 102 patients with 
radiographic suspicion of pancreatic tumor underwent 
endoscopic ultrasonography (EUS) and fine-needle 
aspiration (FNA) of the primary pancreatic mass at 
Washington University School of Medicine and the 
affiliated Siteman Cancer Center (Figure 1A). Besides 
obtaining specimens needed to establish a histologic 
diagnosis, two additional FNA passes from the same 
tumor were collected for CEERTM analysis. A cytological 
diagnosis of adenocarcinoma was initially made in 75 
patients. However, one patient was later diagnosed 
with lung adenocarcinoma with pancreatic metastasis 
and another had extrahepatic cholangiocarcinoma with 
invasion to the pancreatic head. We excluded three other 
patients with PDAC who were lost to follow up from our 
institution. On the other hand, 13 patients had negative 
cytology, i.e. no evidence of malignant cells were detected 
from the initial cytological analysis. Three of these 
patients were later excluded after repeat biopsy showed 
malignancies including lymphoma, cholangiocarcinoma 
and pancreatic adenocarcinoma. Finally, five FNA 
samples showed neuroendocrine tumor and another nine 
were indeterminate due to insufficient tissue material. In 
summary, we focused our analyses on the 70 confirmed 
PDAC specimens with complete clinical follow up, and 
10 specimens with negative (or non-cancerous) cytology 
(Figure 1A). These cytopathologic diagnoses of these ten 
negative samples were: 2 normal lymphoid content, 1 
cystic content with bland epithelium, 5 benign pancreatic 
elements with reactive inflammatory elements, 2 non-
diagnostic with scant cellularity. 
Characteristics of all 102 patients and the 70 PDAC 
patients are provided in Table 1. For CEERTM analysis, all 
FNA samples were collected and immediately processed 
to maximally preserve the phosphorylation status of each 
marker (Figure 1B). A total of 18 markers were assayed in 
the CEERTM platform (see Material and Methods section 
and Table 2). All 70 patients were treated at Washington 
University School of Medicine and followed for up to five 
years or until death.
Comparison of different FNA passes and between 
negative and positive PDAC samples
We first compared whether the signal intensities of 
each marker varied between the two FNA passes from 
each patient. As shown in Table 2, we observed modest 
to moderate degrees of consistency (Spearman’s rho 
coefficients 0.32~0.59) in the signal intensity between 
both passes across all markers. This result is highly 
reflective of the known low cellularity and potentially 
high intratumoral heterogeneity of PDAC tumors [3, 
11], underscoring the need to obtain more than one pass 
for better representation of the whole tumor. To better 
represent tumor cell signaling, the FNA pass with higher 
level of cytokeratin (CK), a specific marker for epithelial 
cells [12], was used in subsequent analyses.
To determine specificity, we next compared the 
intensity of each marker between the 70 PDAC and 10 
Oncotarget24252www.impactjournals.com/oncotarget
Figure 1: A. Flow diagram summarizing workflow of all analyses performed and reasons for inclusion and exclusion of subject for CEER 
studies. B. Representative images of CEERTM arrays obtained from two FNA passes (#1 and #2) of three patients. Signal intensities ranges 
from dark (low) to bright white (high). 
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negative specimens (Table 3). First, we noted significantly 
higher CK signals in PDAC samples, compared to negative 
samples (p = 0.002), indicating presence of neoplastic 
epithelial content in PDAC samples. Remarkably, we 
also noted significantly higher signal intensities in several 
markers in PDAC samples. These include p-HER2 (p = 
0.007), p-HER3 (p = 0.026), total HER2 (p = 0.006), total 
HER3 (p = 0.008), total c-MET (p < 0.001), total IGFR 
(p = 0.012), p-AKT (p = 0.046), p-ERK1/2 (p < 0.001) 
and p-PRAS40 (p = 0.043). In addition, a trend towards 
increased p-c-MET (p = 0.051) in PDAC was seen. Of 
these markers, total c-Met and p-ERK1/2 signals showed 
the strongest statistical difference between PDAC and 
negative samples (both p < 0.001), resonating previous 
reports that c-MET and p-ERK1/2 immunohistochemical 
staining to be markedly elevated in resected PDAC 
samples compared to normal pancreas [13-15]. In 
addition, the stronger p-ERK1/2 signal in PDAC samples 
is consistent with these kinases being key substrates 
that are activated downstream of mutant KRas protein, 
which is present in almost all PDAC [16, 17]. Overall, 
these results demonstrate that the CEERTM technique is a 
robust, highly sensitive and specific tool that is capable 
of detecting salient signaling aberrations from the FNA 
specimens of PDAC patients.
Prognostic significance of measured markers
Apart from having different intensities between 
PDAC and negative samples, we also noted wide patient-
to-patient variation in intensities of all biomarkers, as 
discerned by the high standard deviations relative to 
the mean values of each marker (Table 3). Therefore, 
we hypothesize that the intensity of each marker, which 
represents the activity of various signaling pathways, 
may reflect the biology of the tumor and hence 
patient prognosis. Particularly, since the prognostic 
significance of some of these biomarkers, including 
c-Met, p-AKT and p-ERK1/2 have been published using 
immunohistochemical analyses of resected tumor samples, 
which arguably is the “gold standard” technique, we 
reasoned that being able to recapitulate similar findings 
using FNA specimens would, to some extent, validate the 
accuracy of this novel technique and substantiate its utility 
in future clinical application, particularly for most PDAC 
patients with inoperable disease where large amount of 
tumor specimen is not available. To this end, we followed 
all 70 PDAC patients for up to five years or until death. 
We divided all 70 PDAC patients into two survival groups 
(≤ or > median), using overall median survival (11.5 
Table 1: Characteristics of patients enrolled into studies
Characteristics All patients (N=102) Confirmed PDAC, evaluable (N=70)
Median Age (range)
≤ 65
> 65
67.5 (38-89)
45 (44%)
57 (56%)
69.5 (38-89)
29 (41%)
41 (59%)
Gender (All)
Male
Female
53 (52%)
49 (48%)
34 (48.5%)
36 (51.5%)
Race
Caucasian
Non-Caucasian
89 (87.2%)
13 (12.8%)
60 (85.7%)
10 (14.3%)
Location of tumor
Head
Non-head
57 (55.9%)
45 (44.1%)
38 (54.3%)
32 (45.7%)
Tumor size (mm), median (range) 29 (17-70) 29 (13-70)
Final cytopathologic diagnosis 
               PDAC
               Neuroendocrine
               Indeterminate
               Negative
               Other cancer
74 (72.5%)
6 (5.9%)
9 (8.9%)
10 (9.8%)
3 (2.9%)
Initial Clinical Staging 
Resectable 
Borderline resectable/locally advanced
Metastatic
12 (17.1%)
37 (52.9%)
21 (30%)
Treatment
Surgery
No surgery (chemo ± radiation)
13 (18.5%)
57 (71.5%)
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months, range 0.2 months ~ 5 years) as a cut-off (Table 4). 
When markers between these two survival groups were 
compared, we found that tumors associated with poor 
survival had a strong trend towards having higher total 
c-MET level compared to those with better survival (p = 
0.05), resonating previous report showing c-MET to be 
frequently overexpressed and represents an independent 
poor prognostic factor in resected PDAC patients [18, 19]. 
Interestingly, patients with poor survival had significantly 
lower levels of p-SHC (p = 0.002), p-PRAS40 (p = 0.002) 
and p-AKT (p = 0.025). Partly resonating this finding, 
another study also showed that high p-AKT IHC staining 
in resected PDAC samples was associated with better 
patient prognosis [20].
Besides these biomarkers, clinical parameters 
such as clinical stage (including tumor size and lymph 
node status), tumor grade, age at diagnosis, medical 
comorbidities all have significant prognostic implication in 
PDAC patients. All these individual parameters culminate 
into a composite decision of surgical resection, which 
to date is the single most important prognostic factor in 
the outcome of PDAC patients [21]. Of all 70 PDAC 
patients we analyzed, patients who underwent curative 
resection (N = 13, or 18.6%) had a median survival of 
20.8 months (range 5.1 months ~ alive at 46 months) 
compared to 8.2 months (range 0.2~33 months, all died) 
for those who could not be resected (N = 57, or 81.4%, 
Wilcoxon p = 0.003). Among these 70 patients, we did not 
detect statistically significant differences in survival based 
on age, tumor size, nodal status, stage, or tumor grade, 
probably due to small sample size and the fact that most 
patients were diagnosed at inoperable stages. Of the 57 
non-operable patients, patients with locally-advanced (N 
= 37) or metastatic disease (N = 20) had a median OS 
of 9.7 and 6.7 months respectively, which did not reach 
statistical significance (Wilcoxon P = 0.36) probably due 
to small sample size and the inherent aggressive nature of 
this disease. 
We next explored the prognostic impact of each 
marker among the inoperable patients (N = 57), which 
is rarely reported in the literature due to the limited 
availability of PDAC tissues from these patients. By 
focusing on these patients, we believe we could more 
accurately capture the biological role of each marker in 
the natural progression of PDAC without the dramatic 
interference of surgical removal. Therefore, any markers 
later found to have prognostic impact could have a 
larger therapeutic implication in the future as most 
PDAC patients are either diagnosed at, or eventually 
will progress to, advanced stage. To this end, we divided 
all 57 patients into two groups using median OS (8.2 
months) as a cut-off, and compared the intensity of all 
markers between these two groups (Table 4). Again, we 
found that patients will poorer prognosis had significantly 
higher expression levels of total c-MET (p = 0.027). 
Interestingly, these patients also had significantly higher 
levels of p-SHC and p-PRAS40 (p = 0.006 and p = 0.032, 
respectively). Importantly, patients with poorer prognosis 
were significantly older (mean 72.4 years old) compared 
to those with better prognosis (mean 64.5 years old, p = 
Table 2: Spearman correlation coefficients of each marker between two passes 
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0.018), consistent with published literature showing older 
age as a poor prognostic marker [22].
Independent validation of prognostic significance 
of c-MET using PDAC tissue microarray
While the robust quantitative capability of the 
CEERTM platform has enabled prognostication to be 
ascribed to certain markers such as total c-Met, p-SHC 
and p-PRAS40, further validation is needed. First, high 
level of c-MET immunohistochemical staining in resected 
PDAC tumors has already been reported by different 
groups to be a poor prognostic marker [18, 19]. Second, 
to further confirm this finding, we performed c-MET IHC 
staining on an independent PDAC tissue microarray built 
at our institution. Using the MetMab visual IHC scoring 
criteria (0 to 3+) that is widely adopted [23, 24] (Figure 
2A), we found that the overall expression of c-MET is high 
(MetMab IHC score 2+ or 3+) in 53 out of 140 samples (or 
37.9%) of all PDAC samples. Consistent with our findings 
from the CEERTM platform, high c-MET IHC score is 
associated with poor prognosis in this independent cohort 
of patients (p = 0.03) (Figure 2B). On further analysis of 
PDAC samples, we indeed found significant correlation 
between the intensities of total and phospho-c-MET 
signals (Spearman r 0.64, p < 0.0001; Figure 2C), further 
supporting targeting c-MET to improve the outcome for 
PDAC patients. Overall, our results further substantiate 
the quantifying power of the CEERTM platform, rendering 
it extremely useful in future clinical trial design. 
DISCUSSION
Development of a powerful “functional” diagnostic 
is direly needed to monitor treatment response in the era 
of targeted therapy. The described CEERTM platform is 
particularly powerful in many aspects. First, this platform 
provides, in addition to expression levels, activation status 
of multiple key signaling molecules, which is impossible 
with current transcriptomic or genomic techniques. In 
PDAC, inhibitors that target the key KRas effectors such 
as the Raf-MEK-ERK and PI3K-AKT-mTOR pathways 
are being actively pursued in clinical trials, albeit with 
little success due to rapid emergence of various different 
resistance mechanisms including kinome reprogramming 
[26]. While these mechanisms can be readily identified, 
and overcome using cultured cells in the lab, being able 
to do so in the clinic in real time is essential in initial 
clinical trial allocation, and informing combinatorial 
strategies if no response is seen. To this end, the CEERTM 
technique could potentially provide a comprehensive, 
quantifiable signaling changes across multiple signaling 
pathways within the tumor tissues before and after 
Table 3: Comparison of overall marker intensities between negative vs PDAC specimens
Oncotarget24256www.impactjournals.com/oncotarget
Table 4: Prognostic significance of age and tested markers in PDAC patients
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therapeutic intervention. Second, the ultra-sensitivity 
of this platform allows analysis to be performed using 
scant amount of tissues such as FNA samples, which 
is especially attractive for clinical trials on pancreatic 
cancer, where tissues are limited and prone to degradation 
by catalytic enzymes in the pancreas. Third, the CEERTM 
platform provides clear proteomic distinction between 
normal pancreatic and PDAC tissues, indicating robust 
specificity. For instance, significantly higher signal 
intensity of EGFR/HER signaling, total c-MET, total 
IGFR, p-AKT, p-ERK1/2 and p-PRAS40 were seen in 
PDAC compared to non-cancerous samples. Of these 
markers, enhanced phosphorylation of ERK1/2, AKT 
and PRAS40 are all known events driven by the KRas 
oncoprotein. Therefore, these markers could serve as 
readouts in clinical trials for various inhibitors against the 
KRas effectors. Forth, processing of tumor specimens and 
data analysis are relatively less sophisticated than genomic 
or transcriptomic tools, which will diminish both cost and 
turnaround time. In summary, all these advantageous 
features render the CEERTM technique an extremely 
attractive companion diagnostic in future clinical trial 
design. 
An important finding from analyzing the result 
from CEERTM is the wide patient-to-patient variability 
in the signal intensity of each marker. This finding is 
reflective of the highly heterogeneous biology of PDAC, 
as supported by discovery of various molecular subtypes 
of PDAC based on genomic and transcriptomic analyses 
[2-4]. On this basis, the CEERTM platform may be able 
to provide essential complementary proteomic data that 
could aid treatment selection and even prognostication. 
Supporting this notion, we showed that high level of 
c-MET expression by CEERTM is associated with inferior 
survival for patients with advanced inoperable PDAC. 
We validated this data by immunohistochemistry, which 
is the most widely accepted technique. In addition, the 
poor prognostication of high c-MET level in PDAC has 
also been published in retrospective analysis [19], and 
preclinical studies also show that activation of c-MET in 
PDAC can enhance proliferation, survival, invasiveness, 
and treatment resistance [14, 25]. Several c-MET 
inhibitors are being evaluated in clinical trials for various 
cancer types including PDAC, with promising results still 
lacking, presumably due to poor patient selection and de 
novo resistance [27]. Biomarkers to predict response such 
Figure 2: Independent validation of prognostic significance of total c-MET IHC staining in PDAC tissue microarray 
from another cohort of 140 patients. A. Representative IHC images showing various assigned intensity of total c-MET staining in 
PDAC tissue microarray. B. Kaplan-Meier survival analysis of patients based on c-MET IHC score. C. Spearman correlation between total 
and phospho-c-MET signals of FNA samples subject to CEERTM.
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as circulating HGF or c-MET levels, c-MET genomic 
amplification or protein overexpression are being assessed. 
To this end, the CEERTM technique could certainly provide 
pre-treatment levels of total and activated c-MET to aid 
patient selection, and importantly, assessment of on-
target effect and potential escape mechanisms at treatment 
failure. 
Intriguingly, our data showed that high 
phosphorylation of SHC and PRAS40 proteins to be 
associated with better prognosis in PDAC patients, which 
have not been reported. In contrast, high p-SHC correlates 
with aggressive features and poor prognosis in gastric 
and breast cancer [28, 29], which underscores caution 
when extrapolating research data from one cancer type 
to another. The SHC proteins consists of three different 
splicing isoforms, p46shc, p52shc and p66shc, and are 
all members of the Src homologous- collagen homologue 
adaptor protein family that have very divergent roles in 
regulating signal downstream of growth factor receptors 
[30]. Since the antibody used in our CEERTM platform 
recognizes all three SHC isoforms, development of 
isoform-specific phospho-SHC antibodies will be 
invaluable in informing the prognostic implication of 
each isoform and provide novel therapeutic opportunities. 
Similarly, the association of higher p-PRAS40 with better 
survival in PDAC is also different from a study in gastric 
cancer, where presence of p-PRAS40 was associated with 
aggressive histologic features and poor prognosis [28]. 
The proline-rich AKT substrate of 40-kDA (PRAS40) 
is a substrate of AKT which functions as an inhibitor to 
mTORC1 complex in regulating glucose metabolism 
[31, 32] . To date, the role of PRAS40 in PDAC is 
largely unclear and should be investigated. Overall, these 
interesting observations underscore the ability of the 
CEERTM in revealing, in an unbiased manner, novel and 
potentially important clues that can be pursued.
There are a few limitations in our study. First, low 
tumor cellularity and tumor heterogeneity remain concerns 
especially in PDAC. Although we focused our analyses 
on the FNA sample that has the higher CK value, signals 
from stromal and immune cells may interfere with the 
readouts we obtained. In future studies, more FNA passes 
should be obtained for analysis of the sample with the 
highest CK value. Second, we are unable to determine the 
prognostic impact of different chemotherapeutic regimens 
on patient survival due to small patient number (N = 57). 
However, all patients received systemic treatment per the 
NCCN guidelines, which include 5-FU or gemcitabine-
based chemotherapy regimens as standard-of-care or part 
of clinical trials. Larger studies in the future are needed 
to confirmed the prognostic impact of individual markers 
examined in our present study. 
In conclusion, we demonstrate, for the first time in 
literature successful utilization of an unbiased, proteomic-
based functional diagnostic that allows comprehensive 
elucidation and quantification of signaling aberrations in 
primary PDAC tumors. We demonstrate that this technique 
is clinically feasible, highly sensitive, specific and reliable. 
In the current era of precision oncology when the use of 
kinase inhibitor is increasingly frequent, this technique 
could provide irreplaceable proteomic information 
within the tumor, which could be critical in assessing 
the treatment effect and providing secondary signaling 
changes that could inform resistance mechanisms. As 
such, we believe this technique has irreplaceable value, 
in complement to genomic and transcriptomic tools, in 
realizing the goals of personalized oncology. 
MATERIALS AND METHODS
Tumor specimen procurement
Tumor specimens were prospectively collected via 
endoscopic ultrasound-guided fine needle aspiration (EUS-
FNA) from 102 patients presenting with a suspicious 
pancreatic mass as summarized in Figure 1A. Informed 
consent, specimen collection and future data collection 
were all conducted under IRB approval (Washington 
University in St. Louis IRB protocol #201106347). In 
addition to the passes obtained for routine clinical care, 
two EUS-FNA passes were performed and immediately 
collected in separate vials containing 100 μl of 
preservation and lysis solution (proprietary information, 
Prometheus Laboratories Inc.). The resulting lysates were 
shipped to Prometheus Laboratories (San Diego, CA) at 
ambient temperature within 48 hours of sample collection, 
and stored at -70oC upon receipt until subsequent CEERTM 
analysis. 
Collaborative enzyme enhanced reactive 
immunoassay (CEERTM)
To measure the expression and activation levels 
of receptor tyrosine kinases and signal transduction 
proteins in clinical specimens, we employed CEERTM, 
a highly sensitive multiplexed immunoarray platform. 
Detailed methods for this technology have been described 
previously [1-5]. Briefly, capture antibodies (Abs) were 
printed on nitrocellulose-coated glass slides (ONCYTER 
Grace Biolabs) using a non-contact printer (Nano-Plotter, 
GeSiM). The spot diameter was approximately 175 μm 
and printed slides were kept in a desiccated chamber at 
room temperature. Capture Abs were printed in triplicate 
and at serial dilution concentrations of 1 mg/mL and 0.5 
mg/mL. Purified mouse-IgGs served as negative controls. 
Immunoarray slide configurations and assay format 
were performed as previously described [1-5]. Briefly, 
immunoarray slides were rinsed with TBST (50 mM 
Tris/ 150 mM NaCl/ 0.1% Tween-20, pH 7.2-7.4) and 
blocked for 1 hour at room temperature (RT). Serially 
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diluted lysate controls in 80 µL dilution buffer (2% BSA/ 
0.1% TritonX-100/ TBS, pH 7.2-7.4) and samples were 
added to designated sub-arrays on slides, then incubated 
overnight at RT. After several washes, slides were 
incubated with two detector Abs (for different epitopes) 
conjugated with glucose oxidase (GO) and horseradish 
peroxidase (HRP) respectively for 2 hours at RT. After 
washing slides with TBST to remove unbound detector 
Abs, GO/HRP-mediated tyramide signal amplification 
process was triggered by adding biotin-tyramide solution 
and incubating for 30 mins. Local deposition of biotin-
tyramide was detected by incubation with streptavidin-
Alexa Fluor647 (Life Technologies, Carlsbad, CA) 
for 40 min. Slides were washed with TBST, dried and 
immediately processed on a high-resolution fluorescence 
microarray scanner (PowerScanner, Tecan). Background-
corrected signal intensities were averaged for capture 
antibodies printed in triplicate. For each marker, a 
standard curve was generated from serially diluted control 
lysates prepared from specific cell lines. HCC827, a 
NSCLC adenocarcinoma cell line carrying EGFR gene 
amplification and exon 19 deletion, was used for EGFR 
and MET quantifications, while breast cancer cell lines 
BT474 and T47D, served for HER2/PRAS40/RPS6 and 
HER3/IGF1R/PI3K/CK quantifications respectively. 
Alternatively, standard curves were generated from 
serially diluted recombinant proteins for AKT, ERK, MEK 
and RSK assays. Each curve was plotted as a function of 
signal intensity measured as relative fluorescence unit 
(RFU) vs. log concentration of cell lysates/ recombinant 
proteins or Computed Unit (CU). The data were fit 
to a five-parameter equation by nonlinear regression, 
simultaneously fitting both dilutions of the capture Ab as 
described previously [10, 33]. CEER measurements are 
determined in Computed Unit (CU). CU is a representation 
of marker expression/ activation in unknown samples 
relative to that of control cell lines with known expression 
/activation levels. Hence, a sample with 1 CU of HER1 
expression has an RFU value equivalent to 1 standard 
reference HCC827 cell. Because expression and activation 
of each marker is determined in unique CEER™ assays 
with different cell line standards, only CU values of the 
same marker across various samples can be compared. 
Pancreatic cancer TMA, c-Met 
immunohistochemistry (IHC) and scoring
The PDAC TMA was constructed from FFPE 
surgical specimens archived at the Department of 
Pathology and Immunology at Washington University 
under IRB approval and was previously published [34, 
35]. Complete treatment history, clinical follow up and 
outcomes were available for all patients. For total c-MET 
staining, antigen-retrieval was performed by incubation in 
0.01 mol/L citrate buffer (pH 6.0) and heating in a pressure 
cooker. Sections were incubated at 4ºC overnight with 
total c-MET antibody (D1C2, Cell Signaling Technology, 
1:200), followed by staining using the DAB Peroxidase 
(HRP) Substrate Kit with Nickel (Vector Laboratories 
cat#SK-4100). Stained slides were digitalized and scored 
independently by a GI pathologist (D.C) in blinded fashion 
using the MetMab IHC scoring method as published [23, 
24]. Briefly, stained tumors were scored between 0-3+ 
based on : 0: no staining or < 50% of tumor cells with any 
intensity; 1+: ≥ 50% of tumor cells with weak or higher 
intensity but < 50% with moderate or higher intensity; 2+: 
≥ 50% of tumor cells with moderate or higher intensity 
but < 50% with strong intensity; 3+: ≥ 50% of tumor cells 
staining with strong intensity). 
Statistical analysis
Due to the presence of detecting limits, all the 
measured markers were analyzed using non-parametric 
tests which were based on relative ranks rather than 
absolute values. The correlation between two FNA passes 
from the same patients were assessed using Spearman 
correlation coefficient. In subsequent analysis, the FNA 
pass with higher cytokeratin (CK) level was retained for 
data analysis. The difference in each marker between 
positive and negative PDAC samples was compared using 
Mann-Whitney rank-sum test. Among these 70 patients 
with positive PDAC, only 2 patients (who happened to 
have the longest follow-up times) were censored and the 
survival times were observed in all other patients. To 
assess the prognostic value of each marker on survival, 
the patients were categorized into 2 groups by median 
survival time, and the between-group difference in 
each marker was then compared using Mann-Whitney 
rank-sum test. The survival curves by other clinical 
characteristics such as stage and grade were also estimated 
using Kaplan-Meier product limit method. Since almost 
all the patients died during follow-up and the estimated 
survival curves were more likely to converge eventually, 
the difference between survival curves were compared by 
Gehan-Breslow-Wilcoxon (Wilcoxon) method (which is 
less sensitive to the proportional hazard assumption). All 
the tests were two-sided with p-value of 0.05 indicating 
significance. The data was analyzed using the standard 
package of SAS (Version 9.3, SAS Institute, Cary, NC).
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